1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Anti-obesity Drugs Market?
The projected CAGR is approximately 26.5%.
U.S. Anti-obesity Drugs MarketU.S. Anti-obesity Drugs Market 26.5 CAGR Growth Outlook 2025-2033
U.S. Anti-obesity Drugs Market by Type (Prescription Drugs, Over-the-counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail, Online Pharmacy), by Forecast 2025-2033
Base Year: 2024
180 Pages
U.S. Anti-obesity Drugs Market 26.5 CAGR Growth Outlook 2025-2033
U.S. Anti-obesity Drugs Market 26.5 CAGR Growth Outlook 2025-2033
Key Insights
The U.S. Anti-obesity Drugs Market size was valued at USD 1.71 USD Billion in 2023 and is projected to reach USD 8.86 USD Billion by 2032, exhibiting a CAGR of 26.5 % during the forecast period. Anti-obesity drugs are medications that were created to facilitate the weight-loss process that is based on suppressing appetite, consuming less metabolism, or absorption of nutrients. They are a very diverse class having appetite suppressors, lipase inhibitors, and serotonin-norepinephrine reuptake inhibitors (SNRIs) as members. Such medications interfere with neural networks or hormones that are often linked to the control of hunger and satiety. In the US, there becomes an application of intermittent fasting as an auxiliary to weight loss regimens is one of the strategies to fight obesity and furthermore, metabolic disorders such as type 2 diabetes. Recent market indices are showing a trend that is inclined towards safe and effective anti-obesity drugs with lesser or no side effects which in turn is creating momentum for research on new ways and formulations to fight obesity and the ever-growing health crisis.
U.S. Anti-Obesity Drugs Trends
- Increasing demand for prescription drugs with proven efficacy and safety
- Growing popularity of over-the-counter weight loss supplements
- Shift towards telehealth and online pharmacy for convenience and accessibility
Driving Forces: What's Propelling the U.S. Anti-Obesity Drugs Market
- Surge in obesity rates due to factors such as unhealthy diets and sedentary lifestyles
- Government initiatives to combat obesity and promote healthy weight management
- Advances in drug development, led to the availability of more effective and tolerable therapies
- Growing awareness of the health risks associated with obesity, including cardiovascular disease, type 2 diabetes, and cancer
Challenges and Restraints in U.S. Anti-Obesity Drugs Market
- Insurance coverage limitations for weight loss treatments
- Potential side effects and safety concerns associated with certain drugs
- Lack of long-term efficacy and sustainability of weight loss results
- Stringent regulatory requirements for drug approval
Emerging Trends in U.S. Anti-Obesity Drugs
- Personalized medicine approaches based on genetic and metabolic profiles
- Combination therapies utilizing multiple drugs to enhance efficacy and reduce side effects
- Digital health solutions for weight loss management, including mobile apps and wearable devices
Growth Catalysts in U.S. Anti-Obesity Drugs Industry
- Investment in research and development of novel therapies
- Government funding for obesity prevention and treatment programs
- Collaboration between healthcare providers, pharmaceutical companies, and research institutions
Market Segmentation: U.S. Anti-Obesity Drugs Analysis
Type:
- Prescription Drugs
- GLP-1 Agonists
- Phentermine and Topiramate
- Lorcaserin
- Naltrexone and Bupropion
- Over-the-counter (OTC)
Distribution Channel:
- Hospital Pharmacy
- Retail and Online Pharmacy
Leading Players in the U.S. Anti-Obesity Drugs Market
- Novo Nordisk A/S
- GSK plc
- VIVUS LLC
- Currax Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sandoz International GmbH (Novartis AG)
- Boehringer Ingelheim International GmbH
Significant Developments in U.S. Anti-Obesity Drugs Sector
- July 2023: Capital Rx partners with Virta Health to launch Rx Reverse, an integrated clinical program for GLP-1 drugs.
- May 2023: Noom launches a telehealth program offering Wegovy and weight loss services.
- December 2022: Amgen Inc. announces positive phase I clinical trial results for AMG 133, demonstrating a 14.5% body weight reduction.
Comprehensive Coverage U.S. Anti-Obesity Drugs Market Report
The report covers the following aspects:
- Detailed market analysis and industry forecasts
- Comprehensive SWOT analysis
- Key market trends and drivers
- Segmentation by type, distribution channel, region
- Regulatory landscape and pricing analysis
- Profiles of leading market players and their strategies
U.S. Anti-obesity Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 26.5% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Technological Developments in Products to Propel Market Growth
- 3.3. Market Restrains
- 3.3.1. Stringent Regulatory Process May Limit the Market Growth
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Prescription Drugs
- 5.1.2. Over-the-counter (OTC
- 5.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.2.1. Hospital Pharmacy
- 5.2.2. Retail
- 5.2.3. Online Pharmacy
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1.
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. Northeast U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 7. Southeast U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 8. Midwest U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 9. Southwest U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 10. West U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2019-2031
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 Novo Nordisk A/S (Denmark)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 GSK plc (U.K.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 VIVUS LLC. (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Currax Pharmaceuticals LLC (U.S.)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 F. Hoffmann-La Roche Ltd (Switzerland)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Pfizer Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Sandoz International GmbH (Novartis AG) (Germany)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Boehringer Ingelheim International GmbH (Germany)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.1 Novo Nordisk A/S (Denmark)
List of Figures
- Figure 1: U.S. Anti-obesity Drugs Market Revenue Breakdown (USD Billion, %) by Product 2024 & 2032
- Figure 2: U.S. Anti-obesity Drugs Market Share (%) by Company 2024
List of Tables
- Table 1: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 2: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Region 2019 & 2032
- Table 3: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2019 & 2032
- Table 4: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2019 & 2032
- Table 5: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 6: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2019 & 2032
- Table 7: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 8: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Region 2019 & 2032
- Table 9: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 10: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Country 2019 & 2032
- Table 11: Northeast U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 12: Northeast U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 13: Southeast U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 14: Southeast U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 15: Midwest U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 16: Midwest U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 17: Southwest U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 18: Southwest U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 19: West U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 20: West U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2019 & 2032
- Table 21: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2019 & 2032
- Table 22: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2019 & 2032
- Table 23: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 24: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2019 & 2032
- Table 25: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 26: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Country 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the U.S. Anti-obesity Drugs Market?
Key companies in the market include Novo Nordisk A/S (Denmark), GSK plc (U.K.), VIVUS LLC. (U.S.), Currax Pharmaceuticals LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sandoz International GmbH (Novartis AG) (Germany), Boehringer Ingelheim International GmbH (Germany).
3. What are the main segments of the U.S. Anti-obesity Drugs Market?
The market segments include Type, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 8.86 USD Billion as of 2022.
5. What are some drivers contributing to market growth?
Rising Technological Developments in Products to Propel Market Growth.
6. What are the notable trends driving market growth?
Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.
7. Are there any restraints impacting market growth?
Stringent Regulatory Process May Limit the Market Growth.
8. Can you provide examples of recent developments in the market?
July 2023 – Capital Rx in partnership with Virta Health and launched Rx Reverse which is a high-touch, provider-led, integrated clinical program. The program has been designed to meet the growing demand for GLP-1 drugs approved for diabetes and weight loss.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in USD Billion and volume, measured in K Units.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "U.S. Anti-obesity Drugs Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the U.S. Anti-obesity Drugs Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the U.S. Anti-obesity Drugs Market?
To stay informed about further developments, trends, and reports in the U.S. Anti-obesity Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.